Compare CCIF & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCIF | XTNT |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 61.7M |
| IPO Year | 2011 | 2009 |
| Metric | CCIF | XTNT |
|---|---|---|
| Price | $2.71 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 107.4K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $0.27 |
| 52 Week High | $5.95 | $0.95 |
| Indicator | CCIF | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 54.01 |
| Support Level | $2.57 | $0.27 |
| Resistance Level | $2.95 | $0.47 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 13.64 | 46.88 |
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.